ArticleFrontiers in immunology2024
CD39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets.
Abstract read
In one paragraph
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.Cancer discovery · 2026Article
- Regulatory T cell approaches for graft-versus-host disease prevention.Current opinion in immunology · 2026Review
- The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance.Frontiers in immunology · 2026Review
- Research Progress of Molecular HDrug design, development and therapy · 2026Review
- The role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.Frontiers in immunology · 2025Article
- CD39Frontiers in oncology · 2025Review
- High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.Molecular therapy. Methods & clinical development · 2024Article
- Review
- Mini-Review: Tregs as a Tool for Therapy-Obvious and Non-Obvious Challenges and Solutions.Cells · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Xiangni Wu *Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Pin-I Chen *Department of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Robert L WhitenerDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, United States.
Matthew S MacDougallDepartments of Medicine and of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States.
Vy M N CoykendallDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, United States.
Hao YanDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Yong Bin KimDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
William HarperDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Shiva PathakDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Bettina P IliopoulouDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Allison HestorDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Diane C SaundersDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Erick SpearsDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Jean SévignyCentre de recherche du centre hospitalier universitaire (CHU) de Québec - Université Laval, Québec City, QC, Canada.
David M MaahsStanford Diabetes Research Center (SDRC), Stanford University School of Medicine, Stanford, CA, United States.
Marina BasinaStanford Diabetes Research Center (SDRC), Stanford University School of Medicine, Stanford, CA, United States.
Seth A SharpDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, United States.
Anna L GloynStanford Diabetes Research Center (SDRC), Stanford University School of Medicine, Stanford, CA, United States.
Alvin C PowersDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Seung K KimDepartment of Developmental Biology, Stanford University School of Medicine, Stanford, CA, United States.
Kent P JensenDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Everett H MeyerDepartment of Medicine, Division of Blood and Bone Marrow Transplantation and Cell Therapy, Stanford University School of Medicine, Stanford, CA, United States.
Funding
YOHIMBINE AS A MODEL OF ORTHOSTATIC INTOLERANCEM01RR000095 · NCRR · VANDERBILT UNIVERSITY · PI MAY, JAMES M. · 1985 to 2008
$38.3MVanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3MTRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI ELASY, TOM A · 1986 to 2011
$28.1MThe Human Islet Distribution Coordinating Center (UC4)UC4DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EVANS-MOLINA, CARMELLA, NILAND, JOYCE CAROL · 2012 to 2017
$25.6MStanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5MIntegrated Islet Distribution Program (U24) - 2021U24DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Carmella Evans-Molina, Joyce Carol Niland · 2021 to 2026
$17.8MMolecular Mechanisms of Postnatal Islet alpha-cell ProliferationR01DK117147 · NIDDK · VANDERBILT UNIVERSITY · PI CHEN, WENBIAO, POWERS, ALVIN C · 2019 to 2023
$3.1MEngineered Immune Cells for T1DR01DK132549 · NIDDK · STANFORD UNIVERSITY · PI MEYER, EVERETT · 2022 to 2025
$3.1MTherapeutic targeting of human islets with recombinant regulatory T cellsU01DK123743 · NIDDK · STANFORD UNIVERSITY · PI KIM, SEUNG K, MEYER, EVERETT · 2019 to 2022
$2.9M30-parameter FACSymphony A3 flow cytometer for Shared Resource LabS10OD026831 · OD · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2019 to 2019
$510kFour Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500kNikon A1Rsi resonant spectral confocal microscopeS10OD010580 · OD · STANFORD UNIVERSITY · PI FULLER, MARGARET T · 2013 to 2013
$377kBLRD VA I01 BX000666NCRR NIH HHS M01 RR000095NCRR NIH HHS S10 RR025518NCRR NIH HHS S10 RR027431NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK116074NIDDK NIH HHS P60 DK020593NIDDK NIH HHS R01 DK117147NIDDK NIH HHS R01 DK132549NIDDK NIH HHS U01 DK123743NIDDK NIH HHS U24 DK098085NIDDK NIH HHS UC4 DK098085NIH HHS S10 OD010580NIH HHS S10 OD026831
Abstract
Human regulatory T cells (Treg) suppress other immune cells. Their dysfunction contributes to the pathophysiology of autoimmune diseases, including type 1 diabetes (T1D). Infusion of Tregs is being clinically evaluated as a novel way to prevent or treat T1D. Genetic modification of Tregs, most notably through the introduction of a chimeric antigen receptor (CAR) targeting Tregs to pancreatic islets, may improve their efficacy. We evaluated CAR targeting of human Tregs to monocytes, a human β cell line and human islet β cells
Indexed as
ApyraseReceptors, Chimeric AntigenT-Lymphocytes, RegulatoryAntigens, CDCytotoxicity, ImmunologicDiabetes Mellitus, Type 1HLA-A2 AntigenHumansInsulin-Secreting CellsIslets of LangerhansT-Lymphocyte SubsetsAntigens, CDApyraseCD39 antigenENTPD1 protein, humanHLA-A2 AntigenReceptors, Chimeric Antigenchimeric antigen receptorcytotoxicityimmunoregulationTreg-regulatory T celltype 1 diabetes
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.